ClinicalTrials.gov · updated 2026-11-09

Which peptides have clinical evidence?

Registered clinical trials for every peptide we cover, counted from the US clinical trial registry. The same measure applied to each, so the answer comes from the data rather than the marketing.

Peptides tracked

Established evidence

Early or ongoing

No registered trials

Peptide	Evidence	Studies	Completed	Highest phase
Glucagon	Established clinical evidence	1534	799	Phase 4
Oxytocin	Established clinical evidence	938	516	Phase 4
Somatropin	Established clinical evidence	820	394	Phase 4
Semaglutide	Established clinical evidence	801	285	Phase 4
Leuprolide	Established clinical evidence	520	226	Phase 4
Liraglutide	Established clinical evidence	520	317	Phase 4
Exenatide	Established clinical evidence	380	243	Phase 4
Octreotide	Established clinical evidence	328	177	Phase 4
Tirzepatide	Established clinical evidence	312	76	Phase 4
Teriparatide	Established clinical evidence	182	114	Phase 4
Dulaglutide	Established clinical evidence	143	88	Phase 4
Desmopressin	Established clinical evidence	127	65	Phase 4
Bivalirudin	Established clinical evidence	92	38	Phase 4
Thymosin alpha-1	Established clinical evidence	67	23	Phase 4
Pramlintide	Established clinical evidence	65	43	Phase 4
Linaclotide	Established clinical evidence	60	39	Phase 4
Teduglutide	Established clinical evidence	50	34	Phase 4
Kisspeptin	Established clinical evidence	36	15	Phase 3
Icatibant	Established clinical evidence	33	21	Phase 4
Sermorelin	Established clinical evidence	27	19	Phase 4
Setmelanotide	Established clinical evidence	27	19	Phase 4
Abaloparatide	Established clinical evidence	25	13	Phase 4
Tesamorelin	Established clinical evidence	24	13	Phase 4
LL-37	Late-stage trials underway	20	5	Phase 3
Thymosin beta-4	Established clinical evidence	18	12	Phase 3
Follistatin	Established clinical evidence	15	7	Phase 4
Bremelanotide	Established clinical evidence	10	9	Phase 4
MOTS-c	Early-stage trials only	5	0	Phase 2
BPC-157	Early-stage trials only	4	1	Phase 2
GHK-Cu	Late-stage trials underway	4	1	Phase 4
Ipamorelin	Early-stage trials only	3	2	Phase 2
Selank	Early-stage trials only	2	1	Not applicable
CJC-1295	Early-stage trials only	1	0	Phase 2
Epitalon	Early-stage trials only	1	0	Early Phase 1
Melanotan II	Early-stage trials only	1	0	Phase 2
TB-500	Early-stage trials only	1	0	Phase 2
AOD-9604	No registered clinical trials	0	0
DSIP	No registered clinical trials	0	0
GHRP-2	No registered clinical trials	0	0
GHRP-6	No registered clinical trials	0	0
Hexarelin	No registered clinical trials	0	0
KPV	No registered clinical trials	0	0
Semax	No registered clinical trials	0	0

Counts are registered studies, not published results. Registration records that a study exists; it is not evidence that a compound works. A peptide with no registered trials has not been formally studied in humans through this registry.

Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine. Last updated 2026-11-09.

Related data

FDA drug shortage tracker →
Which peptide drugs are in shortage now, with the FDA-stated cause
Which peptides are FDA-approved →
Approval status for every peptide, from Drugs@FDA
When peptide drugs go generic →
Patent and exclusivity expiry dates from the FDA Orange Book
Peptide legality by US state →
A sourced verdict for all 50 states
Peptide legality by country →
A sourced verdict for 50 countries